Development of a high throughput screening assay for inhibitors of hedgehog-heparin interactions

Laura R Daye
Willietta Gibson
Kevin P Williams

Department of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC, USA

Abstract: The activity of hedgehog ligand is mediated in part by interactions with heparin and heparan sulfate proteoglycans. In order to identify inhibitors that block the interaction of hedgehog with heparin, we have developed a simple and robust high throughput assay based on fluorescence polarization. This assay utilizing fluorescein-labeled heparin binding to sonic hedgehog N-terminal domain (ShhN) protein was developed and optimized in a 384-well format. ShhN bound to fluorescein-labeled heparin with high affinity ($K_D = 99$ nM) and the interaction was shown to be stable over time and tolerant to dimethyl sulfoxide (DMSO). A panel of unlabeled heparins of varying molecular weights was tested in the assay, with lower IC$_{50}$ values correlating with heparins of increasing size. The assay was automated into two simple steps, and validation with whole DMSO plates yielded a Z’ factor of 0.56, indicating a robust assay for high throughput screening. We predict that this assay will be suitable for identifying chemical probes of hedgehog ligand-heparin interactions. Further, compounds that disrupt the ShhN interaction with heparin and/or heparan sulfate proteoglycans may be considered as potential therapeutics for those cancers driven by Hh ligand overexpression.

Keywords: hedgehog, heparin, fluorescence polarization, high throughput screening

Introduction

The hedgehog (Hh) family of secreted proteins (sonic [Shh], indian [Ihh], and desert [Dhh]) play fundamental roles in embryonic development and control the development of many tissues. Many of the downstream signaling events in Hh signaling have been elucidated from genetic and biochemical studies. All Hh ligands seem to bind to the same receptors and regulate the same signaling pathway, but have differing functional responses. The active processed N-terminal domain form of Hh (HhN) is doubly lipid-modified with a cholesterol group on the C-terminus, and a palmitoyl group on the N-terminus of Hh. Despite these lipid modifications, Hh moves beyond the cells where it is expressed and the form of Hh that is diffusible and the mechanism of trafficking is the focus of extensive study. A number of cell surface and extracellular matrix (ECM) molecules have been implicated in modulating Hh diffusion and activity, including hedgehog-interacting protein, interference of hedgehog (ihog), and heparan sulfate proteoglycans (HSPGs). In the current models for Hh trafficking to the responding cell, Hh proteins are released from cells as lipoprotein-associated oligomers. These freely diffusible multimeric forms of Hh travel from Hh-producing cells to Hh-responding cells via interactions with HSPGs, including both glypicans and megalin.

A role for HSPGs in Hh signaling is implicated by restriction in the range of Hh signaling in cells lacking the tout velu gene, which encodes a heparan sulfate
copolymers. The interaction between Shh and HSPGs is critical for cerebellar granule cell proliferation. Direct binding of Hh to HSPGs in cerebellar sections was demonstrated using immunohistochemical approaches, and binding was prevented by heparinase treatment to remove heparan sulfate side chains. The dally-like protein, a member of the glypican family, has been implicated in mediating Hh responsiveness and in Hh trafficking. HSPGs, in addition to controlling Hh movement through the ECM, may also modulate signaling by influencing the signaling apparatus itself. Recently, genetic studies have demonstrated that glypican-3 binds with high affinity to Hh, and inhibits Hh signaling by competition with the Hh receptor, Patched (Ptc), for Hh binding. Mice null for glypican-3 have altered Hh signaling, as assessed by changes in the downstream effectors Gli1 and Ptc.

The high-affinity association of Hh to another cell surface “receptor” involved in Hh activity, ihog, appears to be promoted by heparin binding. Interestingly, a sulfated monosaccharide is trapped at the interface of Hh and ihog. The ability of Hh proteins to interact with heparin was initially established by demonstrating Hh binding to heparin agarose. Furthermore, all Hh proteins were found to possess a consensus (Cardin–Weintraub) sequence for heparin binding. This motif is characterized by a cluster of basic residues in the N-terminal region that allows for electrostatic binding with the negative charges of heparin. Mutations and truncations through this motif showed reduced Hh binding to heparin and reduced Hh activity. In the x-ray structure of the recombinant sonic Hh N-terminal (ShhN) domain, the N-terminal sequence possessing this putative heparin binding site is located towards the N-terminus that extends away from the core structure. Changes in downstream Hh signaling have been observed by studies that reduce HSPG binding to Hh. Mutations through the Cardin–Weintraub sequence of Shh affect the ability of Shh to promote proliferation of cerebellar cells. The formation of complexes between another HSPG, perlecan, and Shh correlated with increasing metastatic potential of a prostate cancer cell line, and silencing of perlecan expression by siRNA decreased Hh signaling.

Characterization of human tumor samples and cell lines, along with inhibitor studies in animal models, have pointed to a central role for the Hh pathway in the growth of many cancer types, with Hh signaling now implicated in approximately 20%–25% of all cancers. Antibodies to Hh were initially used to achieve physiologic blockade of Hh binding and activity. In many of the Hh-pathway-dependent tumors, natural product Hh pathway inhibitors such as cyclopamine and KAAD-cyclopamine decrease the rate of tumor cell proliferation in vitro and in mouse xenograft models. These compounds act by binding to the helical bundle of the coreceptor Smoothened (Smo) and inhibiting Hh signaling. Other small molecule Hh pathway inhibitors have been identified from high throughput screening (HTS) of basal cell carcinoma cell lines and these compounds also target Smo. Subsequent studies with these inhibitors have demonstrated that the use of Hh inhibitors can be a valid therapeutic approach for treating Hh-pathway dependent cancers. Phenotypic screens have also yielded inhibitors targeting the Hh pathway downstream, and these compounds (GANTs) appear to act by targeting the Hh pathway transcription factor Gli. Thus, these current small molecule inhibitors of the Hh pathway almost exclusively target Smo or Gli, and molecules to alternative targets in the Hh pathway are of great interest.

Enzyme-linked immunosorbent assay and biochip formats have been used to develop assays for heparin binding to other proteins. In this study we describe the development of a simple and robust HTS fluorescence polarization (FP) assay based on the interaction of ShhN with heparin. FP assays have been used extensively to identify small molecule inhibitors of many biologic interactions, including other heparin binding partners, with the application of FP to HTS assays having been recently reviewed. We expect that molecules that bind directly to Hh protein and block heparin binding will provide a new set of target-based inhibitors that will expand the currently available Hh pathway inhibitors.

Materials and methods

Materials
Black 384-well low-flange, flat-bottom assay plates (Corning, NY) were used. Porcine intestinal mucosa heparins, low molecular weight (LMW) heparins, fluorescently-labeled heparin, and suramin were from Sigma Aldrich (St Louis, MO). All other reagents were of analytical reagent grade. The gene for human ShhN, comprising residues 24–197, was synthesized (Geneart Inc., Burlingame, CA) and subcloned into the pET19b expression vector (Novagen Inc., Madison, WI). Expression and purification was essentially as previously described.

Fluorescence polarization measurements
Polarization measurements were conducted using a PHER Astar microplate reader (BMG Labtech, Offenburg, Germany) with the FP module. The excitation wavelength was 485 ± 6 nm and emission was detected at 520 nm ± 15 nm. For each
experiment, the gain of the parallel and perpendicular channels was calibrated such that the fluorescent tracer had a polarization value of ~35 millipolarization units (mP).

**Fluorescence polarization assays**

The FP assay was performed in black 384-well plates. Unless stated, the FP assay buffer was 20 mM sodium phosphate pH 6.5, 150 mM NaCl, with 0.5 mM of DTT added for ShhN dilutions. For each FP assay, 25 µL of ShhN at various concentrations were added to each well and a preincubation time of 10 minutes was set. Then 25 µL of 20 nM heparin-fluorescein conjugate (flu-heparin) was added; after 10 minutes of coincubation, the FP values were read. The final volume per well was 50 µL. All assays were performed in triplicate.

For competition assays, 1 µL each of heparin unlabeled salt or suramin at different concentrations and 25 µL of 200 nM ShhN were preincubated for 10 minutes before adding the flu-heparin tracer. For blank measurements, a mixture containing the same components (except the labeled heparin) was used. All measurements were performed in a final dimethyl sulfoxide (DMSO) concentration of 1%.

**FP data analysis**

The FP values were expressed in mP units. Data analysis was conducted using PHARStar software V1.60 (BMG Labtech, Germany), as well as GraphPad Prism v5.0 (GraphPad Software Inc., San Diego, CA). All dissociation constants (K_d) and inhibition constants (IC_{50}) values were determined using nonlinear regression.

**Automation**

The validation experiments were performed using Multidrop® 384 bulk dispensers (ThermoScientific, Hudson, NH) for assay additions and a Biomek® NX (Beckman Coulter Inc., Fullerton, CA) for DMSO/compound additions to 384-well plates.

**Estimation of assay quality**

The Z’ factor was used to assess the quality of the assay and estimate the screening window. The Z’ factor incorporates both the dynamic range of the assay as well as well-to-well variability. Values are obtained by running one whole 384-well plate of maximum (max) signal control and one whole 384-well plate of minimum (min) signal control. Z’ factor was calculated using the formula:

\[ Z' = 1 - (3SD_{\text{max}} + 3SD_{\text{min}})/(\text{mean}_{\text{max}} - \text{mean}_{\text{min}}) \]

Where SD = standard deviation, max = maximum signal, min = minimum signal.

**Cell-based assay for hedgehog activity**

The pluripotent mesenchymal cell line C3H10T1/2 was obtained from ATCC (Manassas, VA) and maintained in Dulbecco’s modified Eagle medium containing 10% fetal bovine serum. The assay was performed essentially as described previously, with cells plated in 96-well plates at 5000 cells/well. Twenty-four hours later, ShhN protein was added and the cells were incubated for a further four days. Cells were then lysed and assayed for alkaline phosphatase (AP) activity (a marker for differentiation into an osteoblast lineage) using the chromogenic substrate pNPP and read at 405 nm. Typical dose responses were carried out in the range of 0.1 to 10 µg/mL ShhN protein. The EC_{50} value is defined as the concentration of ligand giving half maximal activity.

For competition experiments, ShhN was kept at a fixed concentration of 2.0 µg/mL, and various concentrations of competitors were added directly in the wells containing cells. Half maximal effective concentration (EC_{50}) constant and inhibition constant (IC_{50}) values were determined in GraphPad 5.0 with nonlinear regression.

**Results**

**Detection of ShhN-heparin binding using fluorescence polarization**

Direct binding of Hh to heparin has been demonstrated previously using surface plasmon resonance (SPR) and chromatographic formats. As a more amenable HTS assay, we have assessed the feasibility of using the homogeneous FP format as the basis for developing a simple and robust primary assay for identifying inhibitors of the Hh-heparin interaction. Polarization experiments were conducted in 384-well plates using flu-heparin and purified ShhN domain. A schematic for the FP assay is shown in Figure 1. Binding of the flu-heparin tracer to ShhN leads to an increase in the size of the flu-labeled complex and a decrease in rotational motion that results in the emitted light being polarized and higher mP values. Addition of molecules that block the ShhN/flu-heparin interaction will result in a lowered mP signal.

For optimal sensitivity, the flu-heparin concentration was set to produce a total fluorescence signal-to-background ratio greater than 20, and this required a concentration of >5 nM (Figure 2a) and results in a constant tracer signal of ~50 mP (Figure 2b). To establish an assay for ShhN binding to
flu-heparin, we first incubated increasing concentrations of ShhN protein with a fixed amount of flu-heparin to assess for saturation binding. When ShhN was added to flu-heparin, a rapid increase in the measured polarization was observed over the polarization of free flu-heparin, with the polarization value reaching a plateau at 10 minutes and remaining constant for at least one hour (Figure 3a).

A saturation binding isotherm constructed by plotting ShhN concentration against mP values shows that ShhN binds flu-heparin in a dose-dependent manner (Figure 3b). As the concentration of ShhN was increased, mP values increased until saturation was reached (Figure 3b). Saturating amounts of ShhN caused an increase in FP of ~75 mP. Nonlinear regression analysis (single-site binding model) was used to fit the data, and an apparent $K_D$ value of 99 nM was determined. This value fits well with that previously reported for murine Shh binding to heparin using an SPR format ($K_D = 67$ nM).49 We would suggest that in our assay, high-affinity heparin binding is occurring primarily with the polybasic stretch of residues localized on the N-terminal part of ShhN (residues 32–38), because we have previously demonstrated that truncating29 or mutating29,32 this region affects Hh activity, including heparin binding.

The pH dependence and DMSO tolerance of the assay was also assessed. Flu-heparin binding to ShhN was the highest at pH 5.5–6.5 and decreased at pH 7.4 (data not shown). The final concentration of DMSO in the assay is critical because most compound libraries are initially solubilized in 100% DMSO then subsequently diluted in an aqueous buffer. Our preferred HTS scheme involves 0.5 $\mu$L of the compounds being prespotted in 384-well plates with a final assay volume of 50 $\mu$L. Master compound plates are 1 mM stock concentration in 100% DMSO. Hence the effect of 1% (v/v) DMSO was tested in the assay and was found not to affect Hh/flu-heparin binding (data not shown). All subsequent assays were performed at a constant 1% DMSO concentration.

**Figure 1** Schematic illustration of a hedgehog-heparin FP assay. Rotational motion of the flu-heparin will be reduced upon binding to ShhN, resulting in an increase in light polarization. Inh that bind ShhN at the heparin binding site will result in an increase in free flu-heparin and a concomitant decrease in light polarization.

**Notes:** ShhN crystal structure figure adapted from Pepinsky et al7 and heparin schematic from Zhang et al.49

**Abbreviations:** Flu, fluorescently-labeled; FP, fluorescence polarization; Inh, inhibitors; ShhN, sonic hedgehog N-terminal domain.
Fluorescence polarization competitive binding studies

For competition binding assays, the concentrations of flu-heparin and ShhN were set to give ~50% of the maximal response to provide good assay sensitivity. Unlabeled heparins of varying molecular weights were assessed as competitors. Addition of various concentrations of the unlabeled 13,000 MW heparin to a mixture of 20 nM flu-heparin and 100 nM ShhN resulted in a dose-dependent decrease in polarization and a calculated IC\textsubscript{50} value of 240 nM (Figure 4a). The heparin molecules tested had differing IC\textsubscript{50} values in the assay, with a correlation found between higher molecular weight of the heparin and better inhibition (Figure 4b). These findings are consistent with the SPR studies indicating that heparin and LMW heparin had differing IC\textsubscript{50} values of 50 and 700 nM, respectively, for blocking heparin binding to mouse ShhN, and that heparins must be larger than an octasaccharide to block Shh-heparin binding.

To assess whether a small molecule could block flu-heparin binding to ShhN, we tested the polyanionic compound, suramin (molecular weigh 1429.17 Da), which has been previously shown to be a competitive inhibitor of the other heparin-binding proteins. We tested suramin in the FP assay for its ability to block the ShhN-heparin interaction (Figure 5). Suramin inhibited this interaction in the FP assay, with an IC\textsubscript{50} value of 4.6 µM, indicating that small molecules could be identified as inhibitors of Hh-heparin binding.

Heparins inhibit ShhN function in the Hh-dependent C3HT101/2 cell assay

The mouse embryonic fibroblast line C3H10T1/2 has been used extensively as an in vitro model and provides a simple system for assessing Hh activity. This cell line is Hh-responsive as
assessed by induction of AP, and has been used by our research group to assess the activity of recombinant Hh proteins and as an assay for inhibitors of Hh signaling. In this assay, ShhN had an EC\textsubscript{50} \textasciitilde 2 \mu g/mL (data not shown). The ability of heparins of varying molecular weights to inhibit Hh activity was also tested in the C3H10T1/2 cell line AP induction assay.

Heparin titrations were made in media, and media alone was used as the negative control. Addition of varying concentrations of the unlabeled 13,000 molecular weight heparin to C3H10T1/2 cells in the presence of 2 \mu g/mL ShhN resulted in a dose-dependent decrease in AP activity and a calculated IC\textsubscript{50} value of 2.56 \mu M (Figure 6a). The heparins inhibited Hh activity in this assay with varying IC\textsubscript{50} values (Figure 6b), and a correlation between the IC\textsubscript{50} values for heparin inhibition in the FP assay (Figure 4b), and the IC\textsubscript{50} values for heparin inhibition in the C3H10T1/2 bioassay (Figure 6b) suggest that this assay will be a good secondary assay to identify small molecule inhibitors that block Hh-heparin binding and Hh activity.

Assay variability
The variability of the ShhN/flu-heparin FP was studied using triplicate 384-well DMSO plates in a typical
“Min-Mid-Max” experiment and determining $Z'$ as a measure of assay quality (Figure 7a). For this HTS version of the assay (Table 1), the ShhN/flu-heparin assay was simplified into an assay consisting of two 25 µL addition steps using Multidrop 384 (Thermo Fisher) bulk dispensers. DMSO plates were used as a preliminary simulation of compound plates. All plates were prespotted with 0.5 µL DMSO using a Biomek NX liquid-handling work station. ShhN was added first, incubated with DMSO for 10 minutes, followed by addition of flu-heparin, and a further 10-minute incubation prior to reading the plates. Initial experiments were conducted to evaluate the robustness of the assay window by measuring statistically significant changes in mP values between no Shh (minimum signal), 50 nM Shh ($<K_d$), and 100 nM Shh ($\sim K_d$). The data yielded a calculated $Z'$ factor for individual plates of 0.56 and a coefficient of variation <10% (Figure 7b), demonstrating a suitable assay window and acceptable variability for HTS. The assay was repeated for a second day with comparable results for $Z'$ and the coefficient of variation (Figure 7b).

**Discussion**

The Hh family of secreted signaling proteins plays a major role in embryonic development and in the development of many cancers. There is growing evidence that HSPGs play a direct role in Hh signaling and diffusion.

<table>
<thead>
<tr>
<th>Heparin MW (Da)</th>
<th>IC$_{50}$ (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3,000</td>
<td>&gt;10</td>
</tr>
<tr>
<td>5,000</td>
<td>1.16</td>
</tr>
<tr>
<td>4,000–6,000</td>
<td>0.69</td>
</tr>
<tr>
<td>13,000</td>
<td>0.24</td>
</tr>
</tbody>
</table>

**Figure 4** Competitive displacement of ShhN/flu-heparin interaction by unlabeled heparins. **A**): Competitive inhibition of ShhN/flu-heparin binding by heparin (13,000 Da) in the FP assay. Increasing concentrations of heparin were incubated with ShhN (100 nM) and flu-heparin (20 nM) for 10 minutes after which FP was measured. **B**): Calculated IC$_{50}$ values for the four heparins tested as competitive inhibitors in the FP assay. Data were analyzed and plotted in Prizm 5.0.

**Abbreviations:** Flu, fluorescently-labeled; FP, fluorescence polarization; ShhN, sonic hedgehog N-terminal domain; MW, molecular weight.
Although HSPGs facilitate the activity of a number of signaling systems, there are few examples of modulators targeting these interactions. Our goal is to identify novel inhibitors of the Hh pathway by targeting the interaction of Hh ligand with HSPGs using Hh-heparin as a model system. First, as described here, we have designed an HTS assay structured to identify molecules that can modulate heparin-Hh interactions. The study presented here provides a simple FP-based assay for measuring the interaction of Hh ligand with heparin and identifying molecules that disrupt this interaction. The FP format was chosen as the basis for developing an Hh-heparin assay for HTS because FP is suitable for measuring protein-HSPG binding and has been used previously to develop an FP HTS assay for heparin-fibroblast growth factor binding.51 FP is also a homogeneous format that allows a relatively simple “mix and read” automation scheme and is less susceptible to interference by fluorescence compounds, a frequent cause of false positives in HTS assays.56

Using our FP-based format, we have demonstrated high-affinity binding of Shh to heparin (K\textsubscript{d} \sim 100 nM) and that unlabeled heparins compete for binding, with increasing heparin size correlating with better inhibition. This finding is consistent with previously published studies reporting that the minimum oligosaccharide size for competing for ShhN binding to heparin must be larger than an octasaccharide.49

The feasibility of identifying small molecules that block ShhN-heparin interactions is shown here by (i) the ability of suramin to block ShhN-flu-heparin binding in our FP assay and (ii) by a reported HTS assay for inhibitors of fibroblast growth factor receptor binding to heparin that identified several potent small molecule inhibitors.51 Suramin was also a weak inhibitor of Hh activity in the C3H10T1/2 assay with an IC\textsubscript{50} value more than \sim 100 \mu M (data not shown). Hence, we observed a correlation between the FP and C3H10T1/2 assays for both the heparin and suramin molecules, with inhibition values in the FP assay approximately five- to 10-fold lower than in the C3H10T1/2 assay.

The Hh-heparin FP assay described in the present study is robust and meets criteria for industry-accepted HTS standards (Z’ > 0.5). To maximize the potential number of hits from a HTS run, the FP assay format was developed and validated, with DMSO or compounds prespotted, followed by ShhN incubation for 10 minutes, followed by flu-heparin addition and 10 minutes’ incubation prior to reading the plate. To address whether these hits also disrupt ShhN already bound to heparin, we plan to use a secondary assay to screen hits versus preformed ShhN/flu-heparin complexes. The unmodified form of ShhN rather than the physiologic doubly lipid-modified ShhN\textsuperscript{6} was used in our FP assay because we could produce the former in amounts sufficient to run a full HTS of 100,000 compounds. Because
we can only produce the lipid-modified form in very limited amounts in a mammalian cell line, our plan is to use the
doubly lipid-modified Shh in a secondary assay to assess
whether hits also block binding of heparin to this form of
Hh.

Due to the nature of heparin-Hh binding through a
charged motif, we would expect to observe a number of false
positives in this assay from a primary screen. Hence, after
identifying hits from an HTS screen, we plan to use a panel
of complementary secondary and counterscreen assays to
eliminate unwanted activities, and identify those compounds
that work by selectively blocking Hh-HSPG binding. Con-
firmed hits from HTS would first be counterscreened using
a biologically unrelated FP assay that we have previously
described measuring fluorescein-peptide binding to heat
shock protein 70.57 This counterscreen should eliminate
compounds that nonspecifically interfere in FP assays. It is
also expected that a number of highly charged compounds
will be selected as Hh-heparin inhibitors from HTS that may
act to inhibit all heparin binding interactions. We plan to use
a published assay measuring heparin-fibroblast growth factor
binding51 as a secondary selectivity assay. Compounds that
selectively block Hh binding to heparin but not the binding
of fibroblast growth factor to heparin would be prioritized
for further study.

Evidence is mounting that a requirement for abnormal
expression of Hh is characteristic of a number of types of can-
cers and has been reported for small-cell lung,58 pancreatic,59
oesophageal,60 prostate,37,61 breast,62,63 colon,64,65 and liver66
cancers. The few current inhibitors identified to date for the
Hh pathway almost exclusively bind to the Smo corecep-
tor or target the Gli transcription factors, and so molecules
directed to alternative targets in the Hh pathway are of great
interest. We expect that the assay described herein will yield

**Figure 6** Heparins block ShhN-mediated induction of AP in the Hh-responsive cell line C3H10T1/2. **A** Serial dilutions of heparin (13,000 Da) were incubated with the C3H10T1/2 cells and ShhN (2 µg/mL) for four days and the resulting levels of the AP measured. **B** Table of calculated IC\textsubscript{50} values for the four heparins tested as inhibitors in the C3H10T1/2 cell assay. Data were analyzed and plotted in Prism 5.0.

**Abbreviation:** Abs, absorbance; AP, alkaline phosphatase; hh, hedgehog; ShhN, sonic hedgehog N-terminal domain; MW, molecular weight.
molecules that bind directly to Hh protein and disrupt HSPG binding, and so will provide a new set of target-based inhibitors that will complement currently available Hh pathway inhibitors. The feasibility of targeting the Hh ligand directly was demonstrated by the recent identification of a natural product-like compound that blocks Hh binding to Ptc, although the binding site for the molecule on Hh has not yet been identified.67 It is possible that compounds identified from a screen of the Hh-heparin FP assay described in this study could eventually lead to therapeutics for the treatment of cancers, such as pancreatic and liver, which are driven by Hh overexpression and with few current treatment options.

Figure 7 ShhN/flu-heparin FP assay variability assessment. A) FP assay validation. 384-well plates were pre-spotted with 0.5 µL of DMSO using a Biomek NX. One plate each was used to determine the maximum signal (■), mid signal (◆) and minimum signal (▲). Using a Multidrop 384, 25 µL of the FP assay buffer was dispensed into the Min plate; for the Mid plate 25 µL of 50 nM ShhN was used; and for the Max plate 25 µL of 100 nM ShhN was added. After 10 minutes of preincubation, 25 µL of 40 nM flu-heparin was dispensed. The FP values were obtained after 10 minutes of coincubation. The data represent mP values measured in individual wells, consisting of 320 replicates for each condition. The experiment was performed independently on two different days. B) The variability for inhibition was determined from the maximum and minimum plates. Z’ factors, stds, and cvs were calculated in Excel.

**Abbreviations:** Flu, fluorescently-labeled; FP, fluorescence polarization; ShhN, sonic hedgehog N-terminal domain; CV, coefficient of variance; std, standard deviation.

<table>
<thead>
<tr>
<th>Day 1</th>
<th>Day 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Min</td>
</tr>
<tr>
<td>average</td>
<td>29.71</td>
</tr>
<tr>
<td>std</td>
<td>2.50</td>
</tr>
<tr>
<td>CV</td>
<td>8.40</td>
</tr>
<tr>
<td>Z’-factor</td>
<td>0.56</td>
</tr>
</tbody>
</table>

**Table 1 Automation protocol for ShhN/flu-heparin FP assay**

<table>
<thead>
<tr>
<th>Step</th>
<th>Event</th>
<th>Parameter</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Pre-spot</td>
<td>0.5 µL</td>
<td>Dispense DMSO/test compound to 384-well plates using Biomek NX</td>
</tr>
<tr>
<td>2</td>
<td>Add</td>
<td>25 µL</td>
<td>Add ShhN to 384-well plates using Multidrop 384</td>
</tr>
<tr>
<td>3</td>
<td>Incubate</td>
<td>10 min</td>
<td>Room temperature</td>
</tr>
<tr>
<td>4</td>
<td>Add</td>
<td>25 µL</td>
<td>Add flu-heparin to 384-well plates using Multidrop 384</td>
</tr>
<tr>
<td>5</td>
<td>Incubate</td>
<td>10 min</td>
<td>Room temperature</td>
</tr>
<tr>
<td>6</td>
<td>Read</td>
<td>FP</td>
<td>BMG PherStar plate reader</td>
</tr>
</tbody>
</table>

**Abbreviations:** DMSO, dimethyl sulfoxide; flu, fluorescently-labeled; FP, fluorescence polarization; ShhN, sonic hedgehog N-terminal domain.
Acknowledgments
The authors would like to thank David Lamson, Kamalika Chakrabarty, Ginger Smith, and Mark Hughes at the Bio-manufacturing Research Institute and Technology Enterprise Institute (North Carolina Central University) for their technical assistance. This work was supported in part by a grant from the Golden LEAF Foundation and funds from the State of North Carolina.

Disclosure
The authors declare no conflict of interest in this work.

References